Literature DB >> 7962683

Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment.

A E Walsh1, P J Cowen.   

Abstract

The acute administration of the antidepressant drug nefazodone (100 mg orally) to healthy male volunteers increased prolactin concentrations in plasma and elevated oral temperature. After repeated treatment with 100 mg of nefazodone twice daily for 7 days, these effects were attenuated. We propose that the ability of nefazodone given acutely to increase prolactin concentrations and oral temperature is mediated via metabolism to the 5-hydroxytryptamine1C (5-HT1C) receptor agonist meta-chlorophenylpiperazine. The attenuation of these effects after subacute treatment could be due to an adaptive down-regulation of 5-HT1C receptors or to direct blockade of 5-HT1C receptors by nefazodone and its metabolite hydroxynefazodone (OH-nefazodone), the concentrations in plasma of which increase substantially during the 7-day treatment period.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962683

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  4 in total

1.  Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects.

Authors:  J Benjamin; B D Greenberg; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

Review 2.  Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.

Authors:  R Davis; R Whittington; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 3.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

4.  Effects of nefazodone on the development of experimentally induced tumors in stressed rodents.

Authors:  Manuel Freire-Garabal; Manuel Rey-Méndez; Luis A García-Vallejo; José Balboa; José M Suárez; Elena Rodrigo; Julio Brenlla; María J Núñez
Journal:  Psychopharmacology (Berl)       Date:  2004-05-26       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.